Glooko has raised a USD 30 million Series D round of funding.
The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic. The new proceeds will accelerate execution of Glooko’s commercial strategy, including increasing adoption of Glooko’s remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional therapy areas, it states in its press release.
Read more: Glooko and Diasend merge
“This is an unprecedented time in healthcare and technology. The demand for our platform demonstrates this sea-change. Glooko has experienced considerable growth, and this funding allows us to build on our strong momentum in providing the advanced technologies we’re known for,” says Russ Johannesson, CEO of Glooko. “Now more than ever, the healthcare industry is seeking new and smarter technologies, whether it’s for patient care or researching new therapies. I am excited to lead the team at Glooko in our mission to improve health outcomes by connecting people with diabetes and other chronic conditions with their healthcare professionals.”
Photo of Anders Sonesson, CEO Glooko Sweden